Detalhe da pesquisa
1.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
N Engl J Med
; 385(13): 1172-1183, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192426
2.
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight.
Epidemiol Infect
; 152: e37, 2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38250791
3.
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
Clin Infect Dis
; 76(3): 398-407, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36210481
4.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863358
5.
Social media and pharmacovigilance: A review of the opportunities and challenges.
Br J Clin Pharmacol
; 80(4): 910-20, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26147850
6.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085049
7.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis
; 22(8): 1131-1141, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550261
8.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
J Infect
; 84(6): 795-813, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405168
9.
Adenovirus Type 7 causing severe lower respiratory tract infection in immunocompetent adults: a comparison of two contrasting cases from an intensive care unit in North West England.
Clin Infect Pract
; 2: 100007, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31886457
10.
Pharmacogenetics of Adverse Drug Reactions.
Adv Pharmacol
; 83: 155-190, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29801574
11.
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
J Infect
; 86(5): 540-541, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055303
12.
The millennial doctor - A blue collar worker?
Future Hosp J
; 4(1): 45-48, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31098285
13.
The Chief Registrar Programme: developing future leaders.
Future Hosp J
; 4(1): 7-8, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31098274
14.
Core medical training, not core medical service provision.
Future Healthc J
; 4(Suppl 2): s29, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31098510